440 U.S. Highway 22 East
135 articles with Amneal Pharmaceuticals
The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on November 6, 2019.
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
MedicaSafe will combine the generic version of Suboxone® (buprenorphine and naloxone) with its smart medication systems to treat opioid dependence
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its generic version of Amicar® (aminocaproic acid oral solution) 0.25g/mL.
Morgan Stanley 17th Annual Global Healthcare Conference in New York on Tuesday, September 10, 2019 at 2:55 p.m. Eastern Time.
Amneal Pharmaceuticals, Inc. announced its results for the second quarter ended June 30, 2019.
Amneal Pharmaceuticals Co-Founders Chirag Patel and Chintu Patel Return as Co-Chief Executive Officers
Amneal Pharmaceuticals, Inc. announced that its Co-Founders, Chirag Patel and Chintu Patel, have been named Co-Chief Executive Officers, effective immediately.
Patent Trial and Appeal Board Oral Hearing Cancelled
Amneal Pharmaceuticals, Inc., announced that it has received approval for, and launched, its generic version of Lyrica® (pregabalin capsules) 25 mg, 50 mg, 75, mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg.
The drug is approved for use for management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, adjunctive therapy for partial-onset seizures in patients 17 years of age and older, fibromyalgia, and neuropathic pain associated with spinal cord injury.
More than 600 employees will lose their jobs as the companies reshape their corporate strategies.
Amneal Pharmaceuticals Announces Restructuring and Costs Savings Plan to Improve Operations and Position the Company for Future Growth
Amneal Pharmaceuticals, Inc. announced a comprehensive restructuring plan designed to reduce its cost base, further right size its organization and optimize its global manufacturing infrastructure.
Amneal did not specify any layoffs as part of the cut, but did note that employees affected by the decision will be provided comprehensive transition plan.
Amneal Pharmaceuticals, Inc. will release its second quarter 2019 financial results on Thursday, August 8, 2019, prior to the open of the U.S. financial markets.
AMNEAL INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX - June 14, 2019
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX).
Amneal Pharmaceuticals, Inc. announced that members of management will participate at the following upcoming investor conferences
AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX).
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that members of management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 21, 2019 at 11:00 a.m. Eastern Time.
AMNEAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Amneal Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amneal Pharmaceuticals, Inc..
Amneal Pharmaceuticals, Inc. announced its results today for the first quarter ended March 31, 2019.